



Supplementary Fig. 3. (A) Ratio of patients suffering chronic kidney disease (CKD) (bezafibrate vs. fenofibrate). (B) Ratio of patients suffering micro- and macroalbuminuria (bezafibrate vs. fenofibrate). Percentages of the participants with CKD or grade A2/A3 albuminuria being treated with bezafibrate or fenofibrate.